+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Peptide Vaccine for Tumor Market by Cancer Type (Breast Cancer, Colorectal Cancer, Lung Cancer), Therapy Type (Multi-Epitope Vaccine, Peptide Conjugate Vaccine, Therapeutic Peptide Vaccine), Route Of Administration, End User - Global Forecast 2025-2030- Product Image
Peptide Vaccine for Tumor Market by Cancer Type (Breast Cancer, Colorectal Cancer, Lung Cancer), Therapy Type (Multi-Epitope Vaccine, Peptide Conjugate Vaccine, Therapeutic Peptide Vaccine), Route Of Administration, End User - Global Forecast 2025-2030- Product Image
New

Peptide Vaccine for Tumor Market by Cancer Type (Breast Cancer, Colorectal Cancer, Lung Cancer), Therapy Type (Multi-Epitope Vaccine, Peptide Conjugate Vaccine, Therapeutic Peptide Vaccine), Route Of Administration, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 188 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6147897
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Peptide Vaccine Immunotherapy for Tumor Treatment Demonstrates Accelerated Innovation and Collaborative Research Synergies

The global push towards more effective and less invasive tumor therapies has accelerated the advancement of peptide vaccines, a cutting-edge immunotherapeutic approach that harnesses the body’s own immune system to identify and eradicate malignant cells. These vaccines consist of short amino acid sequences designed to mimic tumor-associated antigens, thereby educating T cells to target cancer with heightened specificity while minimizing collateral damage to healthy tissue. In recent years, the convergence of genomics, proteomics, and immunology has underpinned a wave of novel peptide candidates tailored to diverse malignancies, signaling a transformative juncture in oncology.


The evolving regulatory landscape and a surge in public and private funding have further propelled the pace of clinical translation. Early-phase trials have revealed encouraging safety profiles and proof-of-concept efficacy signals across various solid tumor types. As stakeholder interest intensifies-from biopharma innovators to academic research centers-collaborative frameworks have emerged to streamline antigen discovery, peptide optimization, and real-world performance evaluation. This dynamic environment demands a systematic review of technological breakthroughs, competitive positioning, and interdisciplinary alliances that shape the trajectory of peptide vaccines for tumor therapy.

Precision Immunotherapy Evolution Signals Paradigm Shift towards Personalized Peptide Vaccines and Multi-Modal Cancer Treatment

The trajectory of peptide vaccines for tumor treatment reflects a paradigm shift as precision immunotherapy moves from conceptual frameworks to tangible patient outcomes. Traditional therapeutic strategies, typified by broad-spectrum chemotherapies and non-specific cytotoxic agents, have given way to molecularly targeted peptides that exploit unique oncogenic mutations and tumor-derived epitopes. This transition underscores a broader movement towards personalized medicine, where each peptide formulation is fine-tuned to an individual’s tumor antigenic profile.


Simultaneously, advances in adjuvant formulations and delivery platforms have unlocked new potential for immunogenicity and sustained immune activation. Nanoparticle carriers, biodegradable polymer matrices, and novel emulsions are redefining the boundaries of peptide stability and bioavailability, enabling more precise control over antigen presentation and immune priming. These technological improvements forge a ready pathway for combination regimens, wherein peptide vaccines synergize with checkpoint inhibitors, adoptive cell therapies, and oncolytic viruses to orchestrate multifaceted anti-tumor responses.


Moreover, regulatory agencies have signaled a willingness to adopt expedited review pathways for innovative immunotherapies demonstrating robust safety and mechanistic rationale. Initiatives such as breakthrough therapy designations and adaptive trial designs reflect an industry-wide commitment to de-risk the clinical development process. These transformative shifts collectively pave the way for a next generation of peptide vaccines that are not only safer but also more precisely integrated into multi-modal treatment regimens.

Strategic Adaptations Emerge as Supply Chain Diversification and Consortium Purchasing Offset 2025 Tariff Challenges

In early 2025, policy adjustments concerning import tariffs have reverberated across the peptide vaccine research and manufacturing ecosystem. The introduction of new levies on key peptide synthesis reagents and specialized raw materials has disrupted established supply chains, prompting immediate adjustments in procurement strategies. Manufacturers have responded by diversifying sourcing to alternate geographies and by accelerating in-house development of proprietary analogs to mitigate tariff-related cost pressures.


At the same time, research institutes and contract development organizations have reengineered their budgets to account for these additional expenses, resulting in tighter collaboration between procurement, regulatory affairs, and R&D teams. These internal realignments have compelled stakeholders to emphasize efficiency in peptide design cycles, optimizing yield and purity while reducing waste. In parallel, some biopharmaceutical players have engaged in consortium-driven initiatives to pool resources for bulk purchasing, thereby diluting the financial impact of new tariffs.


While short-term headwinds have arisen from increased material costs, the industry’s agile response underscores a resilient R&D infrastructure capable of adapting to shifting trade policies. By fostering cross-functional synergy and supply chain diversification, peptide vaccine developers are forging a more robust and self-reliant manufacturing landscape.

In-Depth Segmentation Reveals Distinct Clinical Imperatives across Cancer Types, Formulations, and Delivery Channels

The tumor peptide vaccine sector encompasses a spectrum of oncology sub-segments and therapeutic modalities, each presenting distinct development trajectories and clinical imperatives. Breast, colorectal, lung, and melanoma malignancies are all under active investigation with peptide candidates designed to exploit tumor-specific antigenic signatures. Each cancer type poses unique immunobiological challenges in antigen heterogeneity and microenvironmental suppression, driving research teams to fine-tune epitopes and adjuvants for maximal T-cell activation.


Therapeutic approaches span from single-epitope vaccines optimized for high neoantigen specificity to multi-epitope constructs engineered to broaden immune engagement. Conjugation strategies, wherein peptides are linked to carrier proteins or immune-stimulatory molecules, have gained traction for their enhanced immunogenic profiles. Meanwhile, traditional peptide formulations continue to demonstrate promise in early-phase trials, particularly for tumors with well-characterized antigen landscapes.


Route of administration plays a pivotal role in balancing immunogenicity and patient convenience. Intramuscular injections remain the standard for ease of delivery, while subcutaneous administrations show potential for sustained antigen release. High-control intravenous infusions, though more complex logistically, deliver peptides directly into systemic circulation, offering rapid immune cell exposure. The application setting further differentiates market dynamics: outpatient and private clinics often focus on adjuvant vaccine protocols, whereas general and specialty hospitals integrate peptides into multi-disciplinary treatment centers. Academic and private research labs drive innovation through exploratory trials and preclinical modeling, fueling the continuous refinement of peptide design and delivery.

Global Peptide Vaccine Ecosystem Thrives on Regulatory Harmonization, Translational Networks, and Regional Manufacturing Strengths

Regional analysis underscores how geopolitical, regulatory, and healthcare infrastructure factors shape the pace of peptide vaccine adoption across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. In North and South America, robust clinical trial networks and well-established regulatory frameworks expedite investigational new drug approvals, catalyzing multiple ongoing Phase I and II studies. The presence of leading contract development organizations and world-class academic centers has fostered a culture of translational research, whereby bench discoveries rapidly translate into first-in-human trials.


Across Europe, Middle East, and Africa, regulatory harmonization initiatives and pan-regional funding programs have facilitated cross-border collaboration. European Immuno-Oncology consortia rally academic and industrial stakeholders around shared antigen libraries and standardized assay platforms, while emerging markets in the Middle East and Africa invest strategically in bio-manufacturing capabilities and infrastructure modernization.


In Asia-Pacific, a surge in government incentives and favorable tax regimes has fueled domestic peptide vaccine ventures and joint ventures with multinational firms. China, India, Japan, and Australia stand out for their parallel development of clinical and commercial peptide manufacturing facilities. Collectively, these regions are shaping a dynamic global ecosystem, driving innovation through complementary strengths in research, regulatory agility, and localized production.

Collaborative R&D Investments and Strategic Alliances Propel Innovative Peptide Constructs and Scale-Up Manufacturing

Key industry participants are catalyzing the maturation of peptide vaccines through targeted R&D investments and strategic alliances. Leading biotech firms are advancing multi-epitope constructs, leveraging proprietary adjuvant technologies to amplify immune activation and durability. Specialty pharmaceutical companies focus on conjugate approaches, integrating peptides with immunostimulatory carriers to heighten T-cell trafficking to the tumor microenvironment.


Collaborations between biopharma developers and contract manufacturing organizations have accelerated scale-up capabilities, with modular facilities designed specifically for peptide GMP production. Concurrent academic partnerships ensure continuous antigen discovery and preclinical validation, while venture-backed startups inject disruptive innovation in peptide synthesis chemistry and formulation design.


Cross-sector consortia, supported by government grants and philanthropic foundations, are standardizing immunomonitoring assays to enable head-to-head comparisons of vaccine candidates. By fostering transparent data sharing and best-practice dissemination, these collaborative networks are underpinning a more cohesive development pathway, reducing redundancy and expediting translational milestones.

Implement End-to-End Collaboration and Modular Manufacturing to Accelerate Peptide Vaccine Success in Personalized Oncology

Industry leaders should prioritize a holistic strategy that integrates antigen discovery, formulation science, and adaptive clinical trial designs. By investing in high-throughput neoantigen identification platforms and advanced bioinformatics, organizations can refine target selection and accelerate candidate triage. Simultaneously, establishing flexible manufacturing capabilities-such as modular peptide synthesis lines-will enable rapid scale-up and customization for personalized oncology protocols.


Forming cross-disciplinary consortiums that include immunologists, bioengineers, and clinical oncologists will foster the development of combination regimens that synergize peptide vaccines with emerging immunomodulatory agents. Additionally, forging partnerships with regional manufacturing hubs can mitigate geopolitical supply chain disruptions and optimize cost structures.


Finally, adopting adaptive trial frameworks with biomarker-guided enrollment criteria will enhance the probability of clinical success and unlock regulatory fast-track pathways. By leveraging real-world evidence and decentralized trial models, stakeholders can capitalize on patient diversity and generate robust safety and efficacy datasets more efficiently.

Rigorous Multi-Source Research Integrates Expert Interviews, Clinical Data, and Policy Analysis for Robust Peptide Vaccine Insights

This report synthesizes insights from a rigorous multi-source research process, combining qualitative and quantitative methodologies. Primary research comprised in-depth interviews with leading immuno-oncology experts, manufacturing specialists, and regulatory advisors. Secondary research involved a systematic review of peer-reviewed journals, clinical trial registries, patent filings, and policy documents relevant to peptide vaccine development.


Data triangulation ensured the reliability of findings, as multiple sources were cross-validated to confirm emerging trends and technological breakthroughs. We employed expert panel validation workshops to refine our understanding of key clinical and commercial imperatives, while scenario analysis techniques modeled the impact of regulatory shifts and supply chain disruptions. Continual methodological refinement during the reporting process maintained alignment with the latest industry advancements and stakeholder priorities.

Peptide Vaccines Are Poised to Redefine Oncology Standards through Integrated Immuno-Therapeutic Strategies and Resilient Collaborations

Peptide vaccines stand at the vanguard of a new era in cancer immunotherapy, offering precision-driven options that complement and enhance existing treatment modalities. The convergence of advanced antigen discovery, formulation technologies, and adaptive trial designs has fostered a fertile environment for innovation. By navigating recent tariff-related challenges and harnessing collaborative R&D frameworks, stakeholders have demonstrated resilience and agility in pursuit of clinically transformative outcomes.


Looking ahead, the seamless integration of peptide vaccines into combination regimens, bolstered by real-time biomarker monitoring and decentralized clinical models, will dictate the pace of adoption. Regional strengths-from North American trial networks to Asia-Pacific manufacturing accelerators and European regulatory harmonization-will collectively shape the global trajectory of this promising therapeutic class.


As the immuno-oncology landscape continues to evolve, the strategic imperatives for developers, contract manufacturers, and healthcare providers are clear: invest in end-to-end capabilities, foster open collaboration, and remain agile in response to policy shifts. Through these concerted efforts, peptide vaccines are poised to redefine the standard of care for many solid tumor indications, bringing the promise of precision immunotherapy to patients worldwide.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Cancer Type
    • Breast Cancer
    • Colorectal Cancer
    • Lung Cancer
    • Melanoma
  • Therapy Type
    • Multi-Epitope Vaccine
    • Peptide Conjugate Vaccine
    • Therapeutic Peptide Vaccine
  • Route Of Administration
    • Intramuscular
    • Intravenous
    • Subcutaneous
  • End User
    • Clinics
      • Outpatient Clinics
      • Private Clinics
    • Hospitals
      • General Hospitals
      • Specialty Hospitals
    • Research Institutes
      • Academic Institutes
      • Private Research Labs

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan

This research report delves into recent significant developments and analyzes trends in each of the following companies:

  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • AstraZeneca plc
  • Amgen Inc.
  • Novartis AG
  • Sanofi S.A.
  • BioNTech SE

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Integration of personalized neoantigen mapping into peptide vaccine design for tumor specificity
5.2. Development of next generation T cell epitope-prediction algorithms for optimized vaccine efficacy
5.3. Adjuvant innovation focusing on STING agonists to potentiate anti-tumor immune response in peptide vaccines
5.4. Emergence of nanoparticle-based delivery platforms for enhanced stability and targeted tumor peptide delivery
5.5. Clinical integration of peptide vaccines with checkpoint inhibitors for synergistic tumor immunotherapy
5.6. Adoption of multi-epitope peptide vaccine constructs to address tumor heterogeneity across cancer subtypes
5.7. Expansion of bioinformatics-driven neoantigen identification pipelines to accelerate personalized vaccine manufacturing
5.8. Regulatory progress in accelerated approval pathways for peptide-based tumor vaccine clinical trials
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Peptide Vaccine for Tumor Market, by Cancer Type
8.1. Introduction
8.2. Breast Cancer
8.3. Colorectal Cancer
8.4. Lung Cancer
8.5. Melanoma
9. Peptide Vaccine for Tumor Market, by Therapy Type
9.1. Introduction
9.2. Multi-Epitope Vaccine
9.3. Peptide Conjugate Vaccine
9.4. Therapeutic Peptide Vaccine
10. Peptide Vaccine for Tumor Market, by Route Of Administration
10.1. Introduction
10.2. Intramuscular
10.3. Intravenous
10.4. Subcutaneous
11. Peptide Vaccine for Tumor Market, by End User
11.1. Introduction
11.2. Clinics
11.2.1. Outpatient Clinics
11.2.2. Private Clinics
11.3. Hospitals
11.3.1. General Hospitals
11.3.2. Specialty Hospitals
11.4. Research Institutes
11.4.1. Academic Institutes
11.4.2. Private Research Labs
12. Americas Peptide Vaccine for Tumor Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Peptide Vaccine for Tumor Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Peptide Vaccine for Tumor Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Merck & Co., Inc.
15.3.2. Bristol-Myers Squibb Company
15.3.3. Pfizer Inc.
15.3.4. GlaxoSmithKline plc
15.3.5. Johnson & Johnson
15.3.6. AstraZeneca plc
15.3.7. Amgen Inc.
15.3.8. Novartis AG
15.3.9. Sanofi S.A.
15.3.10. BioNTech SE
16. Research AI17. Research Statistics18. Research Contacts19. Research Articles20. Appendix
List of Figures
FIGURE 1. PEPTIDE VACCINE FOR TUMOR MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CANCER TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CANCER TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. PEPTIDE VACCINE FOR TUMOR MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. PEPTIDE VACCINE FOR TUMOR MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. PEPTIDE VACCINE FOR TUMOR MARKET: RESEARCHAI
FIGURE 24. PEPTIDE VACCINE FOR TUMOR MARKET: RESEARCHSTATISTICS
FIGURE 25. PEPTIDE VACCINE FOR TUMOR MARKET: RESEARCHCONTACTS
FIGURE 26. PEPTIDE VACCINE FOR TUMOR MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. PEPTIDE VACCINE FOR TUMOR MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY MELANOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY MELANOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY MULTI-EPITOPE VACCINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY MULTI-EPITOPE VACCINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY PEPTIDE CONJUGATE VACCINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY PEPTIDE CONJUGATE VACCINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY THERAPEUTIC PEPTIDE VACCINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY THERAPEUTIC PEPTIDE VACCINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY PRIVATE CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY PRIVATE CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY GENERAL HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY GENERAL HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY SPECIALTY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY SPECIALTY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY PRIVATE RESEARCH LABS, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY PRIVATE RESEARCH LABS, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2030 (USD MILLION)
TABLE 61. AMERICAS PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 62. AMERICAS PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 63. AMERICAS PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 64. AMERICAS PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 65. AMERICAS PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 66. AMERICAS PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 77. UNITED STATES PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 78. UNITED STATES PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 79. UNITED STATES PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 80. UNITED STATES PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 81. UNITED STATES PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 82. UNITED STATES PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 83. UNITED STATES PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 84. UNITED STATES PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 87. UNITED STATES PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 88. UNITED STATES PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 93. CANADA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 94. CANADA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 95. CANADA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 96. CANADA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 97. CANADA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 98. CANADA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 99. CANADA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 100. CANADA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 101. CANADA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 102. CANADA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 103. CANADA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 104. CANADA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 105. CANADA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
TABLE 106. CANADA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2030 (USD MILLION)
TABLE 107. MEXICO PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 108. MEXICO PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 109. MEXICO PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 110. MEXICO PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 111. MEXICO PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 112. MEXICO PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 113. MEXICO PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 114. MEXICO PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 115. MEXICO PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 116. MEXICO PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 117. MEXICO PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 118. MEXICO PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 119. MEXICO PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
TABLE 120. MEXICO PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2030 (USD MILLION)
TABLE 121. BRAZIL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 122. BRAZIL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 123. BRAZIL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 124. BRAZIL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 125. BRAZIL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 126. BRAZIL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 127. BRAZIL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 128. BRAZIL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 129. BRAZIL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 130. BRAZIL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 131. BRAZIL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 132. BRAZIL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 133. BRAZIL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
TABLE 134. BRAZIL PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2030 (USD MILLION)
TABLE 135. ARGENTINA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 136. ARGENTINA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 137. ARGENTINA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 138. ARGENTINA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 139. ARGENTINA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 140. ARGENTINA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 141. ARGENTINA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 142. ARGENTINA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 143. ARGENTINA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 144. ARGENTINA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 145. ARGENTINA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 146. ARGENTINA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 147. ARGENTINA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
TABLE 148. ARGENTINA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 159. EUROPE, MIDDLE EAST & AFRICA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 160. EUROPE, MIDDLE EAST & AFRICA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 161. EUROPE, MIDDLE EAST & AFRICA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
TABLE 162. EUROPE, MIDDLE EAST & AFRICA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2030 (USD MILLION)
TABLE 163. EUROPE, MIDDLE EAST & AFRICA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 164. EUROPE, MIDDLE EAST & AFRICA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 165. UNITED KINGDOM PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 166. UNITED KINGDOM PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 167. UNITED KINGDOM PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 168. UNITED KINGDOM PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 169. UNITED KINGDOM PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 170. UNITED KINGDOM PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 171. UNITED KINGDOM PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 172. UNITED KINGDOM PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 173. UNITED KINGDOM PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 174. UNITED KINGDOM PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 175. UNITED KINGDOM PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 176. UNITED KINGDOM PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 177. UNITED KINGDOM PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
TABLE 178. UNITED KINGDOM PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2030 (USD MILLION)
TABLE 179. GERMANY PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 180. GERMANY PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 181. GERMANY PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 182. GERMANY PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 183. GERMANY PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 184. GERMANY PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 185. GERMANY PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 186. GERMANY PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 187. GERMANY PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 188. GERMANY PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 189. GERMANY PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 190. GERMANY PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 191. GERMANY PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
TABLE 192. GERMANY PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2030 (USD MILLION)
TABLE 193. FRANCE PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 194. FRANCE PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 195. FRANCE PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 196. FRANCE PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 197. FRANCE PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 198. FRANCE PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 199. FRANCE PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 200. FRANCE PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 201. FRANCE PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 202. FRANCE PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 203. FRANCE PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 204. FRANCE PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 205. FRANCE PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
TABLE 206. FRANCE PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2030 (USD MILLION)
TABLE 207. RUSSIA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 208. RUSSIA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 209. RUSSIA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 210. RUSSIA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 211. RUSSIA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 212. RUSSIA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 213. RUSSIA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 214. RUSSIA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 215. RUSSIA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 216. RUSSIA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 217. RUSSIA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 218. RUSSIA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 219. RUSSIA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
TABLE 220. RUSSIA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2030 (USD MILLION)
TABLE 221. ITALY PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 222. ITALY PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 223. ITALY PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 224. ITALY PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 225. ITALY PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 226. ITALY PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 227. ITALY PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 228. ITALY PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 229. ITALY PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 230. ITALY PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 231. ITALY PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 232. ITALY PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 233. ITALY PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
TABLE 234. ITALY PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2030 (USD MILLION)
TABLE 235. SPAIN PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 236. SPAIN PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 237. SPAIN PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 238. SPAIN PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 239. SPAIN PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 240. SPAIN PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 241. SPAIN PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 242. SPAIN PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 243. SPAIN PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 244. SPAIN PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 245. SPAIN PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 246. SPAIN PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 247. SPAIN PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
TABLE 248. SPAIN PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2030 (USD MILLION)
TABLE 249. UNITED ARAB EMIRATES PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 250. UNITED ARAB EMIRATES PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 251. UNITED ARAB EMIRATES PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 252. UNITED ARAB EMIRATES PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 253. UNITED ARAB EMIRATES PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 254. UNITED ARAB EMIRATES PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 255. UNITED ARAB EMIRATES PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 256. UNITED ARAB EMIRATES PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 257. UNITED ARAB EMIRATES PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 258. UNITED ARAB EMIRATES PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 259. UNITED ARAB EMIRATES PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 260. UNITED ARAB EMIRATES PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 261. UNITED ARAB EMIRATES PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
TABLE 262. UNITED ARAB EMIRATES PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2030 (USD MILLION)
TABLE 263. SAUDI ARABIA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 264. SAUDI ARABIA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 265. SAUDI ARABIA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 266. SAUDI ARABIA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 267. SAUDI ARABIA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 268. SAUDI ARABIA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 269. SAUDI ARABIA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 270. SAUDI ARABIA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 271. SAUDI ARABIA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 272. SAUDI ARABIA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 273. SAUDI ARABIA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 274. SAUDI ARABIA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 275. SAUDI ARABIA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
TABLE 276. SAUDI ARABIA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2030 (USD MILLION)
TABLE 277. SOUTH AFRICA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 278. SOUTH AFRICA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 279. SOUTH AFRICA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 280. SOUTH AFRICA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 281. SOUTH AFRICA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 282. SOUTH AFRICA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 283. SOUTH AFRICA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 284. SOUTH AFRICA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 285. SOUTH AFRICA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 286. SOUTH AFRICA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 287. SOUTH AFRICA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 288. SOUTH AFRICA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 289. SOUTH AFRICA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
TABLE 290. SOUTH AFRICA PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2030 (USD MILLION)
TABLE 291. DENMARK PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 292. DENMARK PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 293. DENMARK PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 294. DENMARK PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 295. DENMARK PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 296. DENMARK PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 297. DENMARK PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 298. DENMARK PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 299. DENMARK PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 300. DENMARK PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 301. DENMARK PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 302. DENMARK PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 303. DENMARK PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
TABLE 304. DENMARK PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2030 (USD MILLION)
TABLE 305. NETHERLANDS PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 306. NETHERLANDS PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 307. NETHERLANDS PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 308. NETHERLANDS PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 309. NETHERLANDS PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 310. NETHERLANDS PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 311. NETHERLANDS PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 312. NETHERLANDS PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 313. NETHERLANDS PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 314. NETHERLANDS PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 315. NETHERLANDS PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 316. NETHERLANDS PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 317. NETHERLANDS PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
TABLE 318. NETHERLANDS PEPTIDE VACCINE FOR TUMOR MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2030 (USD MILLION)
TABLE 319. QATAR PEPTIDE VACCI

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Peptide Vaccine for Tumor Market report include:
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • AstraZeneca plc
  • Amgen Inc.
  • Novartis AG
  • Sanofi S.A.
  • BioNTech SE

Related Topics

Related Reports

Neoantigen Cancer Vaccine Market by Neoantigen Type (Personalized Neoantigens, Shared Neoantigens), Therapeutic Target (Immune Checkpoint Blockade, Tumor Neoantigens), Vaccine Platform, Administration Route, End User - Global Forecast 2025-2030 - Product Image

Neoantigen Cancer Vaccine Market by Neoantigen Type (Personalized Neoantigens, Shared Neoantigens), Therapeutic Target (Immune Checkpoint Blockade, Tumor Neoantigens), Vaccine Platform, Administration Route, End User - Global Forecast 2025-2030

  • Report
  • 198 Pages
  • Global
From
Cancer Vaccines Market by Product Type, Formulations, Administration Pathway, Development Phase, Indication, End-User - Global Forecast 2025-2030 - Product Image

Cancer Vaccines Market by Product Type, Formulations, Administration Pathway, Development Phase, Indication, End-User - Global Forecast 2025-2030

  • Report
  • 182 Pages
  • Global
From
Neoantigen Cancer Vaccine Market Report and Forecast 2023-2031 - Product Image

Neoantigen Cancer Vaccine Market Report and Forecast 2023-2031

  • Report
  • 140 Pages
  • Global
From
Cancer Vaccines - Competitive landscape, 2023 - Product Image

Cancer Vaccines - Competitive landscape, 2023

  • Report
  • 500 Pages
  • Global
From
Personalized Cancer Vaccines Market Report 2025 - Product Image

Personalized Cancer Vaccines Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.